FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
+20%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$632M
AUM Growth
+$632M
(+2.7%)
Cap. Flow
-$29.6M
Cap. Flow
% of AUM
-4.68%
Top 10 Holdings %
Top 10 Hldgs %
39.33%
Holding
49
New
13
Increased
6
Reduced
19
Closed
11
Top Buys
| 1 |
Natera
NTRA
|
$19.8M |
| 2 |
Arcellx
ACLX
|
$17.9M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$16.5M |
| 4 |
Harrow
HROW
|
$14.7M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$14.3M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$28.7M |
| 2 |
Immunovant
IMVT
|
$18.4M |
| 3 |
DexCom
DXCM
|
$18.2M |
| 4 |
Alphatec Holdings
ATEC
|
$14.2M |
| 5 |
IDEAYA Biosciences
IDYA
|
$14M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $36.7M | 5.82% | 359,114 +106,838 | +42% | +$10.9M |
|
2
argenx
ARGX
$43.6B
| $29.5M | 4.67% | 54,440 -25,538 | -32% | -$13.8M |
|
3
Insmed
INSM
$28.8B
| $26M | 4.12% | 356,451 +33,091 | +10% | +$2.42M |
|
4
Mirum Pharmaceuticals
MIRM
$3.71B
| $25.3M | 4% | 647,611 -55,787 | -8% | -$2.18M |
|
5
Vaxcyte
PCVX
$4B
| $24.2M | 3.84% | 211,985 -48,296 | -19% | -$5.52M |
|
6
Axsome Therapeutics
AXSM
$6.05B
| $22.9M | 3.63% | 255,294 -81,952 | -24% | -$7.37M |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $22.9M | 3.62% | 1,187,165 +546,776 | +85% | +$10.5M |
|
8
Ascendis Pharma
ASND
$11.8B
| $22.5M | 3.56% | 150,593 -35,988 | -19% | -$5.37M |
|
|
9
Natera
NTRA
$23.1B
| $19.8M | 3.13% | +155,650 | New | +$19.8M |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $18.6M | 2.95% | 254,800 -92,543 | -27% | -$6.77M |
|
11
Crinetics Pharmaceuticals
CRNX
$2.92B
| $18.1M | 2.86% | 353,376 -15,926 | -4% | -$814K |
|
12
Transmedics
TMDX
$3.92B
| $17.9M | 2.84% | 114,247 -25,533 | -18% | -$4.01M |
|
|
13
Arcellx
ACLX
$3.85B
| $17.9M | 2.83% | +214,298 | New | +$17.9M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $16.6M | 2.62% | 178,929 -5,972 | -3% | -$552K |
|
|
VRNA
15
Verona Pharma
VRNA
$9.16B
| $16.5M | 2.61% | +572,928 | New | +$16.5M |
|
16
Vertex Pharmaceuticals
VRTX
$100B
| $16.4M | 2.59% | 35,222 -15,470 | -31% | -$7.19M |
|
17
Biohaven
BHVN
$1.63B
| $15.8M | 2.5% | 315,816 -50,203 | -14% | -$2.51M |
|
18
Establishment Labs
ESTA
$1.2B
| $15.4M | 2.45% | 357,003 -12,977 | -4% | -$562K |
|
19
Merus
MRUS
$4.98B
| $15.4M | 2.44% | 308,014 -13,892 | -4% | -$694K |
|
20
Oric Pharmaceuticals
ORIC
$994M
| $14.9M | 2.35% | 1,451,037 -64,923 | -4% | -$665K |
|
21
Intuitive Surgical
ISRG
$170B
| $14.9M | 2.35% | 30,254 -11,647 | -28% | -$5.72M |
|
|
22
Harrow
HROW
$1.44B
| $14.7M | 2.32% | +326,582 | New | +$14.7M |
|
23
Vera Therapeutics
VERA
$1.38B
| $14.4M | 2.28% | 326,494 +113,550 | +53% | +$5.02M |
|
|
BCAX
24
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $14.3M | 2.27% | +562,391 | New | +$14.3M |
|
25
Geron
GERN
$893M
| $14.2M | 2.25% | +3,124,967 | New | +$14.2M |
|